Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.

急性心肌梗死（AMI）和随之而来的心力衰竭（HF）是全世界死亡和残疾的主要原因之一。因此，仍然需要新的治疗干预措施来保护心脏免受急性缺血/再灌注损伤，以减少心肌梗塞面积并预防 AMI 患者发生心力衰竭。然而，已被证明在临床前动物研究中有益的心脏保护干预措施的临床转化一直具有挑战性。未能将心脏保护转化为患者利益的一个可能主要原因是，在进行临床评估之前，缺乏对有前景的心脏保护干预措施的功效进行严格和系统的体内临床前评估。为了解决这个问题，我们提出了一套体内循序渐进的标准，用于IM证明心脏保护治疗的临床前评估（“IMPACT”），供研究人员在开始临床研究之前考虑采用，其目的是目的是提高将新型心脏保护干预措施转化为临床环境以造福患者的可能性。